Abbott Laboratories

New York Stock Exchange
Back to all articles
Slightly Bullish +25

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

AI-generated analysis

📈 Abbott Laboratories shares returned +8.2% over the past month, outperforming the Zacks S&P 500 composite which saw no change.

💰 The company is expected to post quarterly earnings of $1.28 per share, reflecting a +1.6% year-over-year increase.

📊 Consensus sales estimates for the current quarter stand at $12.53 billion, indicating a +12.4% year-over-year change.

✅ Abbott surpassed consensus EPS and revenue estimates two times each over the last four quarters.

🏆 The company reported actual quarterly revenues of $11.16 billion, beating the consensus estimate by 1.31%.

📉 Despite strong fundamentals, Abbott is currently rated Zacks Rank #4 (Sell) due to recent changes in earnings estimates.

⚖️ Valuation metrics place Abbott at par with peers, resulting in a 'C' grade on the Zacks Value Style Score.

🔮 The consensus EPS estimate for the current fiscal year is $5.48, representing a +6.4% increase from the prior year.

📅 For the next fiscal year, the projected consensus EPS is $6.06, indicating a +10.6% growth trajectory.

⚠️ The Zacks Rank #4 suggests that Abbott may underperform the broader market in the near term.

Bullish Signals
  • Abbott Laboratories has outperformed the S&P 500 with an 8.2% return over the past month while the index remained flat.
  • The company is projected to deliver a 10.6% increase in earnings per share for the next fiscal year, reaching $6.06.
  • Abbott recently beat consensus estimates for both EPS and revenue in its last reported quarter with surprises of +0.88% and +1.31% respectively.
  • The company has a track record of surpassing analyst expectations, beating EPS and revenue targets two times each over the last four quarters.
  • Revenue growth remains strong with current fiscal year estimates projecting a 13.9% increase to $50.49 billion.
Risk Factors
  • Abbott Laboratories currently holds a Zacks Rank #4 (Sell), which indicates potential near-term underperformance relative to the broader market.
  • The consensus earnings estimate for the current quarter has remained unchanged over the last 30 days, suggesting a lack of upward revision momentum.
Full Analysis
Abbott Laboratories (ABT) has been a trending stock, outperforming the S&P 500 with an 8.2% return over the past month compared to the industry's 4.1% gain. Analysts at Zacks prioritize earnings projections for fair value determination, noting that while recent media rumors often drive short-term trends, fundamental factors like earnings estimate revisions are crucial for buy-and-hold decisions. The company is expected to report quarterly earnings of $1.28 per share, representing a 1.6% year-over-year increase, with the consensus estimate remaining unchanged over the last 30 days. For the current fiscal year, the consensus EPS estimate stands at $5.48 (a 6.4% increase), and for the next fiscal year, it is projected at $6.06 (a 10.6% increase). Revenue estimates are also robust, with current quarter sales expected at $12.53 billion. Abbott recently reported revenues of $11.16 billion in its last quarter, beating the consensus estimate by 1.31%, while EPS came in at $1.15 versus a consensus of $1.09. The company has surpassed consensus estimates for both EPS and revenue two times each over the last four quarters. Despite strong historical performance and solid growth projections, Abbott currently holds a Zacks Rank #4 (Sell) due to the size of recent changes in consensus estimates. Valuation analysis indicates that Abbott is trading at par with its peers, receiving a 'C' grade on the Zacks Value Style Score based on traditional and unconventional valuation metrics. While the company demonstrates consistent revenue growth and earnings beats, the Zacks Rank #4 suggests potential near-term underperformance relative to the broader market. Investors are advised to consider these fundamental factors alongside market buzz when evaluating the stock.